Transfusion associated graft versus host disease
- PMID: 14727344
Transfusion associated graft versus host disease
Abstract
Transfusion associated graft versus host disease (TA-GVHD) results from engraftment of viable donor T-lymphocytes in recipient that can not recognize or destroy them. It is seen in immunocompromised patients and pre-mature neonates. It can also occur in immunocompetent individuals receiving blood from first-degree relatives. It has emerged as single most common cause of death resulting from transfusion. Patients with B-cell malignancies appear to be especially at risk. TA-GVHD is associated with 80-90% mortality. Death most commonly occurs due to infection or haemorrhage secondary to pancytopenia. It is therefore important to prevent its occurrence. Prevention can be achieved either by complete removal of T-lymphocytes from donors blood or by abolishing their proliferating potentials. Available methods of leuko-depletion are not effective in preventing TA-GVHD. Only effective way is to inactivate T-lymhocytes. This can be achieved by irradiating blood product with gamma or X-ray irradiation. The concerns about malignant transformation of cells or reactivation of intracellular viruses have not been proved so far. Newer technologies for T-cell inactivation, which are not based on irradiation, are currently under trial.
Similar articles
-
Prevention of transfusion-associated graft-vs-host disease.Arch Pathol Lab Med. 1989 Mar;113(3):285-91. Arch Pathol Lab Med. 1989. PMID: 2645855 Review.
-
Graft-versus-host disease: introduction and prospect.Fukushima J Med Sci. 1993 Dec;39(2):63-7. Fukushima J Med Sci. 1993. PMID: 7927136
-
Mechanism of transfusion-associated graft-versus-host disease.Fukushima J Med Sci. 1993 Dec;39(2):69-75. Fukushima J Med Sci. 1993. PMID: 7927137 Review.
-
Transfusion-associated graft-versus-host disease.Transfus Med Rev. 2009 Jan;23(1):62-71. doi: 10.1016/j.tmrv.2008.09.006. Transfus Med Rev. 2009. PMID: 19056035 Review.
-
Transfusion-associated graft-versus-host disease.Vox Sang. 2008 Aug;95(2):85-93. doi: 10.1111/j.1423-0410.2008.01073.x. Epub 2008 Jun 9. Vox Sang. 2008. PMID: 18544121 Review.
Cited by
-
Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells.PLoS One. 2012;7(8):e43298. doi: 10.1371/journal.pone.0043298. Epub 2012 Aug 14. PLoS One. 2012. PMID: 22905251 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical